MA
$31.95
-0.63
(-1.93%)
As of Oct 22, 2026, 9:31 PM EDT
Price history
Maze Therapeutics Inc (MAZE) is trading down at $31.95 (-1.93%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: January 31, 2025 · $16.00 offering · NASDAQ · View IPO details →
Maze Therapeutics Inc revenue & net income history (FY2024–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|
| Income statement | ||
| Revenue | $167.5M | — |
| Operating income | $57.6M | −$142.9M |
| Operating margin | 34.4% | — |
| Net income | $52.2M | −$131.1M |
| Net margin | 31.2% | — |
| EPS (diluted) | $1.25 | −$3.05 |
| Balance sheet | ||
| Cash and equivalents | $196.8M | $189.2M |
| Total assets | $240.5M | $397.1M |
| Total liabilities | $43.6M | $42.2M |
| Shareholders' equity | −$311.2M | $355.0M |
| Cash flow | ||
| Operating cash flow | $76.0M | −$111.9M |
| Capital expenditure | $1.15M | $794.0K |
| Free cash flow | $74.8M | −$112.7M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.50M | — | $0 | $0 | — | — | $20.0M | $0 |
| Growth (year over year) | — | — | — | −100.0% | — | — | — | — |
| Operating income | −$24.2M | — | −$35.4M | −$36.5M | −$33.0M | −$38.1M | −$26.6M | −$48.0M |
| Operating margin | −969.2% | — | — | — | — | — | −132.8% | — |
| Net income | −$24.8M | — | −$32.8M | −$33.7M | −$30.1M | −$34.6M | −$24.2M | −$44.7M |
| Net margin | −990.1% | — | — | — | — | — | −121.0% | — |
| EPS (diluted) | −$10.25 | — | −$1.15 | −$0.77 | −$0.66 | −$0.47 | −$0.45 | −$0.76 |
| Balance sheet | ||||||||
| Cash and equivalents | $149.6M | $196.8M | $294.4M | $264.5M | $316.8M | $189.2M | $198.8M | $202.6M |
| Total assets | — | $240.5M | $332.8M | $303.5M | $422.1M | $397.1M | $419.7M | $531.6M |
| Total liabilities | — | $43.6M | $40.8M | $41.3M | $42.6M | $42.2M | $78.0M | $78.5M |
| Long-term debt | — | — | — | — | — | — | $38.8M | $39.0M |
| Shareholders' equity | −$284.5M | −$311.2M | $292.1M | $262.2M | $379.4M | $355.0M | $341.7M | $453.1M |
| Cash flow | ||||||||
| Operating cash flow | −$23.2M | — | −$29.5M | −$30.1M | −$24.6M | −$27.7M | −$39.1M | −$15.1M |
| Capital expenditure | $103.0K | — | $299.0K | $393.0K | $68.0K | $34.0K | $93.0K | $107.0K |
| Free cash flow | −$23.3M | — | −$29.8M | −$30.4M | −$24.7M | −$27.8M | −$39.2M | −$15.2M |
From Maze Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Maze Therapeutics Inc
- Headquarters
- South San Francisco, California From SEC filings, Oct 2026
Recent News (3)
-
Canaccord initiates Maze Therapeutics stock rating at Buy on kidney drug potential
Canaccord initiates Maze Therapeutics stock rating at Buy on kidney drug potential
-
Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares
Maze Therapeutics CEO Jason Coloma sells $932,259 in Maze shares
-
Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight The Pompe disease market is estimated to change significantly during the forecast period (2026–2036), owing to the launch of novel therapies including MZE001 (S-606001; Shionogi and Maze Therapeutics)…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International